Filgotinib治疗活动性银屑病关节炎患者驱动临床改善的药效学效应:EQUATOR试验
基于II期EQUATOR试验(NCT03101670)121例活动性银屑病关节炎患者,分析filgotinib(FIL)治疗前后外周蛋白与基因表达变化。基线炎症标志物与多项PsA临床指标显著相关(PASI除外,对应Th17标志物);FIL持续抑制免疫基因转录、增加循环B细胞,第4天B细胞、炎症细胞因子和中性粒细胞变化与第16周临床指标变化相关,SEM提示FIL通过降低IL-23 p19和IL-12 p40改善PASI。
要点
- 基线炎症标志物与多项PsA临床指标显著相关,PASI对应Th17标志物。
- FIL治疗持续抑制免疫基因及通路转录,持续增加循环B细胞比例及成熟B细胞。
- 第4周B细胞、全身炎症细胞因子和中性粒细胞变化与第16周临床指标变化相关。
核心结论
- FIL治疗快速下调与PsA疾病活动相关的炎症和免疫通路,对应PsA临床改善。
研究设计与样本
- II期EQUATOR试验(NCT03101670)评估Janus激酶1偏好性抑制剂FIL在PsA患者中的疗效。
- 对121例患者基线及治疗后的外周蛋白和基因表达水平采用线性混合效应模型进行重复测量分析。
- 采用中介分析和结构方程模型(SEM)探讨FIL第4周对第16周下游临床改善的作用机制。
主要发现
- 基线分析显示炎症标志物与多项PsA临床指标显著相关,但PASI除外,PASI对应Th17标志物。
- FIL治疗导致免疫基因和通路转录持续抑制,循环B细胞比例及成熟B细胞持续增加,对其他细胞组分有一过性影响。
- 中介分析显示第4周B细胞、全身炎症细胞因子和中性粒细胞的变化与第16周临床指标的变化相关。
- SEM提示FIL通过降低IL-23 p19和IL-12 p40蛋白改善PASI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of this study was to identify protein and transcriptional biomarkers and pathways associated with baseline disease state, the effect of filgotinib (FIL) treatment on these biomarkers, and to investigate the mechanism of action of FIL on clinical improvement in patients with active psoriatic arthritis (PsA). METHODS: The phase II EQUATOR (NCT03101670) trial evaluated the efficacy of FIL, a Janus kinase 1-preferential inhibitor, in patients with PsA. Peripheral protein and gene expression levels in association with clinical state at baseline and post-treatment were assessed in 121 patients using linear mixed effects models for repeated measures analyses. Mediation analysis and structural equation modelling (SEM) were performed to investigate the mechanism of action of FIL at week 4 on downstream clinical improvement at week 16. RESULTS: Baseline analyses showed that markers of inflammation were significantly associated with multiple PsA clinical metrics, except for Psoriasis Area and Severity Index (PASI), which corresponded to Th17 markers. FIL treatment resulted in sustained transcriptional inhibition of immune genes and pathways, a sustained increase in B-cell fraction and mature B-cells in circulation, and a transient effect on other cell fractions. Mediation analysis revealed that changes in B cells, systemic inflammatory cytokines and neutrophils at week 4 were associated with changes in clinical metrics at week 16. SEM suggested that FIL improved PASI through reduction of IL-23 p19 and IL-12 p40 proteins. CONCLUSIONS: Our results revealed that FIL treatment rapidly downregulates inflammatory and immune pathways associated with PsA disease activity corresponding to clinical improvement in PsA. TRIAL REGISTRATION NUMBER: NCT03101670.
引用
- Chandran V, Malkov VA, Ito KL, et al. Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial. RMD Open. 2023. PMID: 37945284. doi:10.1136/rmdopen-2023-003550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。